Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Cash Flows From Operating Activities:
Net income (loss)	$ 19,981	$ (48,690)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Amortization of deferred revenue	(6,150)	(7,042)
Depreciation and amortization	2,480	2,136
Stock-based compensation	10,880	4,212
Change in fair value of common stock warrant liability	6,487	(4,401)
Provision for bad debt	291
Changes in operating assets and liabilities:
Accounts receivable, net	(25,711)	113
Inventories, net	(5,165)	108
Prepaid expenses and other assets	12	173
Accounts payable and other accrued obligations	7,677	7,072
Accrued compensation and related expenses	(497)	(928)
Accrued drug development costs	2,062	(537)
Landlord contributions to tenant improvements		1,446
Deferred revenue and other credits	(55)	16,935
Net cash provided by (used in) operating activities	12,292	(29,403)
Cash Flows From Investing Activities:
Maturities of marketable securities	15,157
Purchases of marketable securities	(15,972)	(4,769)
Purchases of property and equipment	(341)	(1,835)
Net cash used in investing activities	(1,156)	(6,604)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock from stock option exercises	1,973	690
Proceeds from contributions to ESPP	398	305
Repayment of capital leases	(15)	(14)
Net cash provided by financing activities	2,356	981
Net increase (decrease) in cash and cash equivalents	13,492	(35,026)
Cash and cash equivalents--beginning of period	53,557	82,336
Cash and cash equivalents--end of period	67,049	47,310
Supplemental Disclosure of Cash Flow Information:
Conversion of preferred stock to common stock	37
Common stock issued for Targent milestone	6,230
Targent milestones included in intangible assets and accrued liabilities	$ 10,159